The CD34<sup>+</sup> Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors

Remberger, Mats; Grønvold, B.; Ali, Maryan; Mattsson, Jonas; Egeland, Torstein; Lundin, Katrin U.; Myhre, Anne Grethe; Abrahamsen, Ingerid Weum; Heldal, Dag; Dybedal, Ingunn; Tjønnfjord, Geir E.; Gedde‐Dahl, Tobias; Fløisand, Yngvar

doi:10.2991/chi.d.200221.001

Cited by 14 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single-centre analysis done in Oslo which studied 189 PBSC recipients from sibling donors concluded that a CD34 cell dose of 6-7 × 10 6 /kg showed better survival and lesser mortality while a dose of <5 × 10 6 /kg had increased relapse but lower GVHD and higher than 6.5 × 10 6 /kg had lower acute GVHD. [10] Another study done in 2015 done in 205 patients from a single institution concluded that there is no ideal cell dose at transplant within a range of 10 4 -10 5 . [11] Thus, it becomes very important to define the minimum cell dose required to give the best engraftment.…”

Section: Discussionmentioning

confidence: 99%

Effect of CD34+ cell dose on neutrophil and platelet engraftment kinetics in haematopoietic stem cell transplantation – A single-centre experience

Abraham

Pramod

2021

IJPP

View full text Add to dashboard Cite

Objectives: Haematopoietic stem cell transplantation (SCT) is curative for a number of benign and malignant hematological disorders. CD34 expression on haematopoietic progenitor cells is used to assess stem cell content in peripheral blood stem cell and bone marrow grafts. This study evaluated the relationship between numbers of CD34+ cells infused per kg and the timing of neutrophil and platelet engraftment. Materials and Methods: The effect of cell dose was studied in consecutive HSCT patients transplanted between November 2008 and December 2017. Neutrophil engraftment was defined as the first of 2 consecutive days with an absolute neutrophil count >0.5 × 109/L and platelet engraftment as unsupported platelet count >20 × 109/L for 7 days. Results: Of a total of 131 patients, 26 (19.8%) underwent an autologous SCT, while 105 (80.2%) underwent an allogeneic SCT. The median CD34 dose infused in the auto-SCT group was 5.29 × 106 CD34+cells/kg (IQR = 2.95–10.98) and 6.42 × 106 CD34+cells/kg (IQR = 4.20–9.20) in the allo-SCT group (P = 0.773). The median time to neutrophil engraftment in the auto-SCT group was 11 days (range 9.5–12) and in the allo-SCT group was 15 days (range 13–17), P ≤ 0.001. The median time to platelet engraftment in both groups was similar (12 days). When patients were divided into three groups based on CD34 dose (<5, 5–8 and >8), no difference was observed in the time to ANC or platelet engraftment. Similarly, no differences in time to engraftment were noted in each quartile of CD34 dosage in auto- and allo-SCT. Conclusion: Thus, it was concluded that a cell dose of approximately 5 × 106/kg provides reasonably rapid engraftment, with no advantage seen for a higher cell dose of >5.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of CD34+ cell dose on neutrophil and platelet engraftment kinetics in haematopoietic stem cell transplantation – A single-centre experience

Abraham

Pramod

2021

IJPP

View full text Add to dashboard Cite

show abstract

“…In 2006, Bickford et al (2006) reported that these agents (as well as catechin) synergistically stimulated the in vitro proliferation of human bone marrow and human CD34 + and CD133+ cells. CD34 + are often used clinically to quantify H-SC numbers in H-SC transplantation ( Remberger et al, 2020 ). CD133 is a well-characterized biomarker of normal and cancer SCs ( Barzegar Behrooz et al, 2019 ).…”

Section: Clinical Trials With Sc Preparations For Agingmentioning

confidence: 99%

Recent clinical trials with stem cells to slow or reverse normal aging processes

Garay

2023

Front. Aging

View full text Add to dashboard Cite

Aging is associated with a decline in the regenerative potential of stem cells. In recent years, several clinical trials have been launched in order to evaluate the efficacy of mesenchymal stem cell interventions to slow or reverse normal aging processes (aging conditions). Information concerning those clinical trials was extracted from national and international databases (United States, EU, China, Japan, and World Health Organization). Mesenchymal stem cell preparations were in development for two main aging conditions: physical frailty and facial skin aging. With regard to physical frailty, positive results have been obtained in phase II studies with intravenous Lomecel-B (an allogeneic bone marrow stem cell preparation), and a phase I/II study with an allogeneic preparation of umbilical cord-derived stem cells was recently completed. With regard to facial skin aging, positive results have been obtained with an autologous preparation of adipose-derived stem cells. A further sixteen clinical trials for physical frailty and facial skin aging are currently underway. Reducing physical frailty with intravenous mesenchymal stem cell administration can increase healthy life expectancy and decrease costs to the public health system. However, intravenous administration runs the risk of entrapment of the stem cells in the lungs (and could raise safety concerns). In addition to aesthetic purposes, clinical research on facial skin aging allows direct evaluation of tissue regeneration using sophisticated and precise methods. Therefore, research on both conditions is complementary, which facilitates a global vision.

show abstract

“…The remaining 40% of donors usually achieve target yield after repeat PBSC, although 2-5% are poor mobilisers and never achieve target. For recipients, suboptimal CD34 + cell yields from donors result in prolonged engraftment times and increased risk of adverse events such as graft failure, infection, or bleeding (3, 4).…”

Section: Introductionmentioning

confidence: 99%

Scoping review of factors associated with stem cell mobilisation and collection in allogeneic stem cell donors

Peck,

Knapp-Wilson,

Burley

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: There is a large inter-individual variation in CD34+ cell yield after G-CSF mobilisation and collection from peripheral blood in healthy allogenic haematopoietic stem cell donors. Donor characteristics including gender and age, baseline and precollection blood results, mobilisation factors and collection factors have been associated with CD34+ cell concentration in the blood after G-CSF mobilisation and/or CD34+ cell yield after collection. Since the literature reporting these associations is heterogeneous, we here clarify the determinants of CD34+ cell concentration and yield through a scoping literature review. Materials and Methods: MEDLINE, Embase, PubMed and Stem Cell Evidence were searched for studies published between 2000 and 2023. The inclusion criteria were studies of allogeneic donors undergoing G-CSF mobilisation and peripheral blood stem cell collection (PBSC). Eligible studies assessed an outcome of mobilisation or collection efficacy, indicated by the blood CD34+ cell concentration after 4 or 5 days of G-CSF treatment and/or CD34+ cell yield in the first PBSC collection after mobilisation. Included studies assessed associations between these outcomes and donor factors(such as age, gender, weight, ethnicity), mobilisation factors (G-CSF scheduling or dose), collection factors (venous access, processed blood volume) and laboratory factors (such as blood cell counts at baseline and after mobilisation). Results: The 51 eligible studies evaluated between 23 and 20,884 donors. 43 studies were retrospective, 32 assessed blood CD34+ cell concentration after mobilisation and 37 assessed CD34+ cell yield. In studies that recorded both outcomes, blood CD34+ cell concentration always predicted CD34+ cell yield. The most frequently assessed factor was donor age for which most studies reported that younger donors had a higher blood CD34+ cell concentration and CD34+ cell yield. Non-European ancestry was associated with both higher blood CD34+ cell concentration and yield although this finding was inconsistent. Conclusions: There remains poor consensus about the best predictors of blood CD34+ cell concentration and yield that requires further prospective study, particularly of the role of donor ancestry. The current focus on donor gender as a major predictor may require re-evaluation

show abstract

The CD34⁺ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors

Cited by 14 publications

References 34 publications

Effect of CD34+ cell dose on neutrophil and platelet engraftment kinetics in haematopoietic stem cell transplantation – A single-centre experience

Effect of CD34+ cell dose on neutrophil and platelet engraftment kinetics in haematopoietic stem cell transplantation – A single-centre experience

Recent clinical trials with stem cells to slow or reverse normal aging processes

Scoping review of factors associated with stem cell mobilisation and collection in allogeneic stem cell donors

Contact Info

Product

Resources

About

The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors

Cited by 14 publications

References 34 publications

Effect of CD34+ cell dose on neutrophil and platelet engraftment kinetics in haematopoietic stem cell transplantation – A single-centre experience

Effect of CD34+ cell dose on neutrophil and platelet engraftment kinetics in haematopoietic stem cell transplantation – A single-centre experience

Recent clinical trials with stem cells to slow or reverse normal aging processes

Scoping review of factors associated with stem cell mobilisation and collection in allogeneic stem cell donors

Contact Info

Product

Resources

About

The CD34⁺ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors